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Brachytherapy of Skin and Penile Cancer Workshop
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a r t i c l e i n f o a b s t r a c t
Squamous cell cancer of the penis is an uncommon, aggressive malignancy whit an age-
adjustedannual incidenceof oneout of every 100,000men. Surgical amputation (penectomy)
has been considered the gold standard for the treatment of penile cancer, but is associated
with a high level of psychosexual morbidity. Low-dose-rate brachytherapy (BT) consists of
eithermanually afterloaded 192Ir or pulse-dose-rate (PDR) brachytherapyprovides an organ-
sparing alternative, preserving penile morphology and functionality in selected patients
without compromising cure.
Patients: Tumours T1 and T2 N0, up to 4 cm, strictly limited to the glans and not extended
beyond the balano-preputial sulcus are most suitable for BT.
Materials: Pre-drilled Lucite templates and needles.
Implant procedure: A Foley catheter is inserted to determine the exact position of the urethra.
The Paris System of dosimetry is used as a basis for designing the geometry of any individ-
ual implant to meet the requirements of tumour conﬁguration. The distribution, spacing
(median 15mm) and total number of needles depend on tumour size. The needles are pos-
itioned in a square or rectangular array. Planes are oriented with the needles passing from
the dorsal to the ventral surface of the glans. Pre-drilled Lucite templates are used for guid-
ance of needle placement and to maintain parallelism through the duration of the implant.
A Styrofoam collar is positioned around the base of the penis for support and to minimize
unnecessary irradiation of adjacent structures.
Treatment planning: The gross tumour volume (GTV) includes all visible and palpable tumour.
The clinical target volume (CTV) encompasses the GTV plus a safety margin of 5–10mm.
According to the Paris system, prescription is to 85% of the dose rate minima between the
planes. The prescribed dose is generally 60Gy with the treatment completed in about 5 days.
Results: Local control rates obtained with BT ranging 72–80% at 10 years. The penile preser-
vation rate is approximately at 70% at 10 years. The two most common late complications
are: urethral meatal stenosis (9–45%) and soft tissue necrosis (6–26%).
Conclusions: Interstitial brachytherapy is a relatively simple and effective treatment of penile
cancer, with results similar to those obtained with surgery in T1–T2 N0 M0, with high rates
of organ preservation and acceptable toxicity.
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1. Surface HDR brachytherapy in cutaneous
tumours
Dra. María Beatriz Pinar Seden˜o, S◦ Oncología Radioterápica,
Htal Gral de Gran Canaria Dr Negrín.
2. Background
The incidence of skin cancer is rapidly rising, due to popula-
tion’s senescence and the fashionable higher exposure to solar
radiation. Treatment approach must be individualized based
on patient characteristics for improving cosmetic and func-
tional outcome. Brachytherapy constitutes an optimal option
of treatment. High dose rate brachytherapy (HDR-BT) using
surface applicators has shown efﬁcacy in the treatment of
NMSC and shortens the radiation treatment schedule. The use
of custom-made surface moulds is a more ﬂexible technique
and allows treating irregular areas.
With the problems of waiting lists for external radiation
therapy, the use of contact HDR-BT in NMSK would lead to a
more intelligent use of resources.
3. Patients and materials
3.1. Patients
Non-melanoma skin cancer (basal or squamous cell carci-
nomas) as radical treatment, adjuvant therapy after surgery
when margins are compromised or close, recurrent lesions
after surgical procedures and localized less than 5mm deep
cutaneous T lymphoma.
3.2. Materials
Plastic 6 F brachytherapy catheters and cutter device, adapt
thermoplastic balls for personalized applicators (custom-
made moulds), standard applicators (Super Mould or Freiburg
Flap by Nucletron® or similar) and dummy sources for CT-
based simulation.
4. Implant procedure
Depending in locations and geometry of lesions (ﬂat or not
surface), custom-made moulds with thermoplastic balls or
standard applicators are individually selected. Thermoplastic
balls are heated in boiled water. A 0.5 cm width slide is ﬁrstly
adapted over the tumour; brachytherapy catheters are then
placed and covered with another 0.5 cm slide of thermoplastic
material. If a standard applicator is used, catheters are placed
inside the applicator. The tumour can be marked with a thin
wire for making easy the lesion deﬁnition during simulation
CT.
5. Treatment planning
A typical treatment area deﬁnition begins with an assess-
ment of the visible surface lesion, known as the gross tumour
volume (GTV). An additional margin to account for measure-
ment uncertainty and uncertainty in applicator placement
was added; this constitutes the planning target volume
(PTV).
The objective of the treatment planning process for HDR-
BT using the surface applicators is to cover with an optimal
dose the whole PTV deﬁned. Dose prescription varies depend-
ing on the characteristics of the patients:
- Elderly patients, with difﬁcult mobility: hypofractionated
scheme will be chosen, 500 cGy twice a week, 9–10 fractions,
BED: 56–62Gy for acute effects and 72–80Gy, depending on
the kind of treatment (adjuvant or radical) for late effects.
- Younger patients, with a higher possibility of late toxicity,
standard fractionation will be chosen, 200–225 cGy ﬁve days
a week, during 3–5 weeks.
6. Treatment delivery
We use a HDR-microselectrón Unit (Nucletron-Elekta®) for
treatment delivery. Patient is placed in a comfortable posi-
tion, applicator is placed over the PTV, safety guidewire are
retired and catheters are connected with transfer tubes to the
treatment unit.
7. Toxicity and results
Long-term control rates for NMSC treated with external beam
radiation therapy (superﬁcial X-rays, orthovoltage X-rays,
megavoltage photons or electron beam radiation, range from
87% to 100% after a follow up of 2–5 years.
High dose rate brachytherapy with Ir-192 for NMSC has
shown control rates of 92–98% after 5–10 years of follow up.
As a conclusion, clinical results are excellent in terms
of tumour control. Cosmetic results are almost excellent
when standard fractionation is used. With hypofractionated
schemes, a slightly higher rate of telangiectasia or hypocromic
areas has been reported.
Although these excellent control rates, it is frequent to
experience new cutaneous tumours in sites different from
treated areas, so more conservative approaches as HDR-BT are
more suitable for this kind of patients.
